INTRODUCTION: Concern about a testosterone (T)-induced prostate-specific antigen (PSA) increase is often perceived as one of the main limitations in treating hypogonadism even when it is symptomatic, such as in subjects with sexual dysfunction (SD). AIM: The aim of this study was to evaluate the relationship between T and PSA levels in subjects with SD. Methods. We retrospectively evaluated the relationship between T and PSA in 2,291 subjects seeking medical care at our outpatient clinic for SD (sample A). The analysis was then repeated in a selected subpopulation of 1,421 subjects apparently free from prostatic diseases (sample B). MAIN OUTCOME MEASURES: The specific association between PSA levels, circulating androgens, and different clinical signs and symptoms of hypogonadism, as assessed by ANDROTEST structured interview, was evaluated. RESULTS: In both samples A and B, subjects with higher PSA levels reported a lower prevalence of hypogonadism-related symptoms and signs, as well as higher total testosterone (TT), and analogue and calculated free T. However, when the association between PSA and T was evaluated as a function of T deciles, the upper nine groups had similar PSA values, with the lowest demonstrated a significantly reduced PSA (the lowest vs. the rest of the sample: 0.61[0.38-1.23] ng/mL vs. 0.86[0.57-1.44] ng/mL, and 0.51[0.30-0.94] ng/mL vs. 0.73[0.52-1.10] ng/mL, respectively, for samples A and B; both P < 0.0001). Furthermore, when the relationship between hypogonadism (TT < 8 nmol/L) and PSA levels was evaluated according to age, it was significant only in younger subjects, but not in the older ones. CONCLUSIONS: Our data demonstrated that PSA is unrelated to T concentration across most of the T range, except for the most severely T deficient, and that a significant relationship between T and PSA is seen in younger but not in older men.
INTRODUCTION: Concern about a testosterone (T)-induced prostate-specific antigen (PSA) increase is often perceived as one of the main limitations in treating hypogonadism even when it is symptomatic, such as in subjects with sexual dysfunction (SD). AIM: The aim of this study was to evaluate the relationship between T and PSA levels in subjects with SD. Methods. We retrospectively evaluated the relationship between T and PSA in 2,291 subjects seeking medical care at our outpatient clinic for SD (sample A). The analysis was then repeated in a selected subpopulation of 1,421 subjects apparently free from prostatic diseases (sample B). MAIN OUTCOME MEASURES: The specific association between PSA levels, circulating androgens, and different clinical signs and symptoms of hypogonadism, as assessed by ANDROTEST structured interview, was evaluated. RESULTS: In both samples A and B, subjects with higher PSA levels reported a lower prevalence of hypogonadism-related symptoms and signs, as well as higher total testosterone (TT), and analogue and calculated free T. However, when the association between PSA and T was evaluated as a function of T deciles, the upper nine groups had similar PSA values, with the lowest demonstrated a significantly reduced PSA (the lowest vs. the rest of the sample: 0.61[0.38-1.23] ng/mL vs. 0.86[0.57-1.44] ng/mL, and 0.51[0.30-0.94] ng/mL vs. 0.73[0.52-1.10] ng/mL, respectively, for samples A and B; both P < 0.0001). Furthermore, when the relationship between hypogonadism (TT < 8 nmol/L) and PSA levels was evaluated according to age, it was significant only in younger subjects, but not in the older ones. CONCLUSIONS: Our data demonstrated that PSA is unrelated to T concentration across most of the T range, except for the most severely T deficient, and that a significant relationship between T and PSA is seen in younger but not in older men.
Authors: Sarah B Peskoe; Corinne E Joshu; Sabine Rohrmann; Katherine A McGlynn; Sarah J Nyante; Gary Bradwin; Adrian S Dobs; Norma Kanarek; William G Nelson; Elizabeth A Platz Journal: Prostate Date: 2015-04-28 Impact factor: 4.104
Authors: M Gacci; G Corona; G Apolone; A Apolone; M Lanciotti; N Tosi; S Giancane; L Masieri; S Serni; M Maggi; M Carini Journal: Prostate Cancer Prostatic Dis Date: 2010-03-09 Impact factor: 5.554
Authors: Francesco Lotti; Francesca Frizza; Giancarlo Balercia; Arcangelo Barbonetti; Hermann M Behre; Aldo E Calogero; Jann-Frederik Cremers; Felice Francavilla; Andrea M Isidori; Sabine Kliesch; Sandro La Vignera; Andrea Lenzi; Marios Marcou; Adrian Pilatz; Olev Poolamets; Margus Punab; Maria Fernanda Peraza Godoy; Claudia Quintian; Osvaldo Rajmil; Gianmaria Salvio; Osama Shaeer; Wolfgang Weidner; Elisa Maseroli; Sarah Cipriani; Elisabetta Baldi; Selene Degl'Innocenti; Giovanna Danza; Anna Lucia Caldini; Alessandro Terreni; Luca Boni; Csilla Krausz; Mario Maggi Journal: Andrology Date: 2022-07-19 Impact factor: 4.456
Authors: Mauro Gacci; Nicola Tosi; Gianni Vittori; Andrea Minervini; Giovanni Corona; Tommaso Cai; Anna Maria Morelli; Linda Vignozzi; Sergio Serni; Mario Maggi; Marco Carini Journal: Oncol Lett Date: 2013-06-21 Impact factor: 2.967